Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus
Authors:
Open Access
- 13 August 2014
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 28 (10) , 891-902
Abstract
Vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-HT)3, 5-HT7and 5-HT1Dreceptor antagonist, a 5-HT1Breceptor partial agonist, a 5-HT1Areceptor agonist and a 5-HT transporter (SERT) inhibitor. Vortioxetine has been shown to improve cognitive performance in several preclinical rat models and in patients with major depressive disorder. Here we investigated the mechanistic basis for these effects by studying the effect of vortioxetine on synaptic transmission, long-term potentiation (LTP), a cellular correlate of learning and memory, and theta oscillations in the rat hippocampus and frontal cortex. Vortioxetine was found to prevent the 5-HT-induced increase in inhibitory post-synaptic potentials recorded from CA1 pyramidal cells, most likely by 5-HT3receptor antagonism. Vortioxetine also enhanced LTP in the CA1 region of the hippocampus. Finally, vortioxetine increased fronto-cortical theta power during active wake in whole animal electroencephalographic recordings. In comparison, the selective SERT inhibitor escitalopram showed no effect on any of these measures. Taken together, our results indicate that vortioxetine can increase pyramidal cell output, which leads to enhanced synaptic plasticity in the hippocampus. Given the central role of the hippocampus in cognition, these findings may provide a cellular correlate to the observed preclinical and clinical cognition-enhancing effects of vortioxetine.Keywords
This publication has 64 references indexed in Scilit:
- The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant MedicationJournal of Clinical Psychopharmacology, 2011
- Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective studyPsychological Medicine, 2010
- Serotonin increases GABA release in rat entorhinal cortex by inhibiting interneuron TASK-3 K+ channelsMolecular and Cellular Neuroscience, 2008
- Calcium influx through presynaptic 5-HT3 receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studiesNeuroscience, 2004
- A Pharmacological Analysis of an Associative Learning Task: 5-HT1to 5-HT7Receptor Subtypes Function on a Pavlovian/Instrumental Autoshaped MemoryLearning & Memory, 2003
- Presynaptic 5‐HT3 receptor‐mediated modulation of synaptic GABA release in the mechanically dissociated rat amygdala neuronsThe Journal of Physiology, 2000
- EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysisBrain Research Reviews, 1999